Candriam Luxembourg S.C.A. Has $619,000 Position in Redhill Biopharma Ltd. (RDHL)
Candriam Luxembourg S.C.A. held its stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,267 shares of the biotechnology company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Redhill Biopharma were worth $619,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the first quarter valued at $101,000. Family Management Corp acquired a new stake in Redhill Biopharma during the first quarter valued at $163,000. Penserra Capital Management LLC increased its stake in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares in the last quarter. Oppenheimer & Co. Inc. increased its stake in Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 6,172 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Redhill Biopharma during the fourth quarter valued at $266,000. 12.22% of the stock is owned by institutional investors and hedge funds.
Redhill Biopharma Ltd. (NASDAQ:RDHL) opened at 8.54 on Wednesday. Redhill Biopharma Ltd. has a 52-week low of $8.16 and a 52-week high of $15.99. The firm has a 50 day moving average of $8.94 and a 200-day moving average of $9.55. The stock’s market cap is $146.57 million.
Redhill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.02. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million. Equities analysts anticipate that Redhill Biopharma Ltd. will post ($2.34) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Candriam Luxembourg S.C.A. Has $619,000 Position in Redhill Biopharma Ltd. (RDHL)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-has-619000-position-in-redhill-biopharma-ltd-rdhl/1493308.html.
Several analysts have weighed in on RDHL shares. Zacks Investment Research raised shares of Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research note on Tuesday, July 4th. FBR & Co reissued a “buy” rating on shares of Redhill Biopharma in a research note on Friday, June 16th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Thursday, June 15th. Finally, Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Thursday, May 4th.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Redhill Biopharma Ltd. (NASDAQ:RDHL).
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.